Bioequivalence Study of Apixaban 5 mg Film-Coated Tablet

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-15

Study Completion Date

2021-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was an open-label, randomized, single-dose, two-period, two-sequence, cross-over study under fasting condition which included 24 healthy adult male and female subjects. The objective of this study was to find out whether the bioavailability of apixaban 5 mg film-coated tablet produced by PT Dexa Medica in comparison with the comparator drug (Eliquis® 5 mg filmcoated tablet, Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioequivalence Study of Apixaban 5 mg Film-coated Tablets in Healthy Thai Volunteers

NCT06388239

Healthy Volunteer

NOT_YET_RECRUITING PHASE1

Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects

NCT06043297

Antithrombic Drug

COMPLETED PHASE1

Bioequivalence Study of Rivaroxaban 10 mg Film-coated Tablets

NCT06558058

Healthy

COMPLETED PHASE1

Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets

NCT06558045

Healthy

COMPLETED PHASE1

Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects

NCT05841446

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study was to find out whether the bioavailability of apixaban 5 mg film-coated tablet produced by PT Dexa Medica in comparison with the comparator drug (Eliquis® 5 mg filmcoated tablet, Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia). This was an open-label, randomized, single dose, two-period, two-sequence, cross-over study under fasting condition which included 24 healthy adult male and female subjects. The participating subjects were required to have an 8 hours overnight fast and in the next morning (first day of period) were given orally the test drug (apixaban 5 mg film-coated tablet produced by PT Dexa Medica) or the comparator drug (Eliquis® 5 mg Film Coated Tablet, Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia) with 200 mL of water. The subject's oral cavity was checked thoroughly to confirm complete medication and fluid consumption after dosing. Blood samples were drawn before taking the drug (control), and at 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 9.00, 12.00, 24.00, 36.00, and 48.00 hours after drug administration. These blood samples were used to investigate the pharmacokinetic parameters of apixaban following single dose administration. The plasma concentrations of apixaban were determined by using a validated ultra-performance liquid chromatography with tandem mass spectrometry detection (UPLC-MS/MS).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This was a bioequivalence study

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Apixaban 5 mg Film-Coated Tablet PT Dexa Medica

Apixaban 5 mg Film-Coated Tablet (produced by PT Dexa Medica)

Group Type EXPERIMENTAL

Apixaban 5 mg Film-Coated Tablet (produced by PT Dexa Medica)

Intervention Type DRUG

One tablet of the test drug was given orally under fasting condition

Reference Eliquis® 5 mg film-coated tablet, Bristol-Myers Squibb

Eliquis® 5 mg film-coated tablet, Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia

Group Type ACTIVE_COMPARATOR

Eliquis® 5 mg film-coated tablet (Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia)

Intervention Type DRUG

One tablet of the reference drug was given orally under fasting condition

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apixaban 5 mg Film-Coated Tablet (produced by PT Dexa Medica)

One tablet of the test drug was given orally under fasting condition

Intervention Type DRUG

Eliquis® 5 mg film-coated tablet (Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia)

One tablet of the reference drug was given orally under fasting condition

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Able to participate, communicate well with the investigators and willing to provide written informed consent to participate in the study.
2. Healthy male and female subjects with absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history or physical examination during screening and could be considered healthy based on the evaluation.
3. Aged 18 - 55 years inclusive.
4. Preferably non-smokers or smoke less than 10 cigarettes per day.
5. Body mass index within 18 to 25 kg/m2.
6. Normal prothrombin time (PT) and normal partial thromboplastin time (aPTT)
7. Creatinine clearance \> 50 mL/min
8. Vital signs (after 10 minutes rest) must be within the following ranges:

* Systolic blood pressure: 100 - 129 mmHg
* Diastolic blood pressure: 60 - 84 mmHg
* Pulse rate: 60 - 90 bpm.

Exclusion Criteria

1. History of allergy or hypersensitivity or contraindication to apixaban or factor Xa inhibitors or allied drug.
2. Pregnant or lactating female (urinary pregnancy test was applied to female subjects at screening and before taking the study drug).
3. Any major illness in the past 90 days or clinically significant ongoing chronic medical illness.
4. Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver function test (AST, ALT, alkaline phosphatase, total bilirubin, direct bilirubin ≥ 1.5 ULN), renal function test (serum creatinine concentration \> 1.4 mg/dL and ureum ≥ 1.5 ULN), etc.
5. Positive Hepatitis B surface antigen (HBsAg), anti-HCV, or anti-HIV.
6. Clinically significant hematology abnormalities.
7. Positive result for COVID-19 antigen rapid test.
8. Clinically significant electrocardiogram (ECG) abnormalities.
9. Any surgical or medical condition (present or history) which might significantly alter the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal disease including gastric or duodenal ulcers or history of gastric surgery.
10. Past history of anaphylaxis or angioedema.
11. History of drug or alcohol abuse within 12 months prior to screening for this study.
12. Participation in any clinical trial within the past 90 days calculated from the last visit until this study's first dosing day.
13. History of any bleeding or coagulative disorders.
14. History of significant head injury within the last two years.
15. Presence of difficulty in accessibility of veins in left or right arm.
16. A donation or significant blood loss within 90 days before this study's first dosing day.
17. Intake of any prescription, (especially apixaban, other anticoagulants, azole antimycotics), non-prescription drug, (including hormonal contraception), food supplements or herbal medicines within 21 days of this study's first dosing day

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes